PT  - JOURNAL ARTICLE
AU  - Wijk, Gwen van der
AU  - Zamyadi, Mojdeh
AU  - Bray, Signe
AU  - Hassel, Stefanie
AU  - Arnott, Stephen R.
AU  - Frey, Benicio N.
AU  - Kennedy, Sidney H.
AU  - Davis, Andrew D.
AU  - Hall, Geoffrey B.
AU  - Lam, Raymond W.
AU  - Milev, Roumen
AU  - Müller, Daniel J.
AU  - Parikh, Sagar
AU  - Soares, Claudio
AU  - Macqueen, Glenda M.
AU  - Strother, Stephen C.
AU  - Protzner, Andrea B.
TI  - Large Individual Differences in Functional Connectivity in the Context of Major Depression and Antidepressant Pharmacotherapy
AID  - 10.1101/2023.10.17.23297087
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.17.23297087
4099  - http://medrxiv.org/content/early/2023/10/18/2023.10.17.23297087.short
4100  - http://medrxiv.org/content/early/2023/10/18/2023.10.17.23297087.full
AB  - Clinical studies of major depression (MD) often examine differences between groups whilst ignoring within-group variation. However, inter-individual differences in brain function are increasingly recognised as important and may impact effect sizes related to group effects. Here, we examine the magnitude of individual differences in relation to group differences that are commonly investigated (e.g., related to MD diagnosis and treatment response). Functional MRI data from 107 participants (63 female, 44 male) were collected at baseline, 2 and 8 weeks during which patients received pharmacotherapy (escitalopram, N=68), and controls (N=39) received no intervention. The unique contributions of different sources of variation were examined by calculating how much variance in functional connectivity was shared across all participants and sessions, within/across groups (patients vs controls, responders vs non-responders, female vs male participants), recording sessions and individuals. Individual differences and common connectivity across groups, sessions and participants contributed most to the explained variance (>95% across analyses). Group differences related to MD diagnosis, treatment response and biological sex made significant but small contributions (0.3-1.2%). High individual variation was present in multimodal association areas, while low individual variation characterized primary sensorimotor regions. Group differences were much smaller than individual differences in the context of MD and its treatment. These results could be linked to the variable findings and difficulty translating research on MD to clinical practice. Future research should examine brain features with low and high individual variation in relation to psychiatric symptoms and treatment trajectories to explore the clinical relevance of the individual differences identified here.Significance statement Studies on major depression often investigate differences in brain function between groups (e.g., those with/without a diagnosis) with the aim of better understanding this prevalent condition. Our study shows that group differences only tell part of the story, by highlighting strong common and individually unique features of brain network organization, relative to surprisingly subtle features of diagnosis and treatment success. From the overall explained variation in brain connectivity, about 50% was shared across everyone, while another 45% was unique to individuals. Only ∼5% could be attributed to diagnosis, treatment success and biological sex differences. Our results suggest that examining individual differences, and their potential clinical relevance, alongside group differences may bring us closer to improving clinical outcomes for major depression.Trial registration ClinicalTrials.gov: NCT01655706.Competing Interest StatementBenicio N. Frey has received grant/research support from Alternative Funding Plan Innovations Award, Brain and Behavior Research Foundation, Canadian Institutes of Health Research, Hamilton Health Sciences Foundation, J. P. Bickell Foundation, Ontario Brain Institute, Ontario Mental Health Foundation, Society for Women's Health Research, Teresa Cascioli Charitable Foundation, Eli Lilly and Pfizer, and has received consultant and/or speaker fees from AstraZeneca, Bristol-Myers Squibb, Canadian Psychiatric Association, CANMAT, Daiichi Sankyo, Lundbeck, Pfizer, Servier and Sunovion. Roumen V. Milev has received consulting and speaking honoraria from AbbVie, Allergan, Janssen, KYE, Lundbeck, Otsuka, and Sunovion, and research grants from CAN-BIND, CIHR, Janssen, Lallemand, Lundbeck, Nubiyota, OBI and OMHF. Sagar Parikh has been a consultant to Takeda, Bristol Myers Squibb, Lund- beck; has had a research contract with Assurex; has equity in Mensante. Raymond W. Lam has received speaker and consultant honoraria or research funds from AstraZeneca, Brain Canada, Bristol-Myers Squibb, the Canadian Institutes of Health Research (CIHR), the Canadian Network for Mood and Anxiety Treatments, the Canadian Psychiatric Association, Eli Lilly, Janssen, Lundbeck, Lundbeck Institute, Medscape, Otsuka, Pfizer, Servier, St. Jude Medical, Takeda, the University Health Network Foundation, Vancouver Coastal Health Research Institute, Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Healthy Minds Canada, Michael Smith Foundation for Health Research, MITACS, Myriad Neuroscience, Ontario Brain Institute, Otsuka, Unity Health, Viatris, and VGH-UBCH Foundation. Sidney H. Kennedy has received honoraria or research funds from Abbott, Alkermes, Allergan, Boehringer Ingelheim, Brain Canada, CIHR, Janssen, Lundbeck, Lundbeck Institute, Ontario Brain Institute, Ontario Research Fund, Otsuka, Pfizer, Servier, Sunovion, Sun Pharmaceuticals, and holds stock in Field Trip Health. Daniel J. Müller has received consulting and speaking honoraria from Lundbeck and Genomind. Dr Soares has received consulting and speaking honoraria from Pfizer, Otsuka, Bayer, Eisai and research grants from CAN-BIND, CIHR, OBI, and SEAMO. Stephen C Strother is a senior Scientific Advisor and shareholder in ADMdx, Inc., which receives NIH funding, and during the period of this research, he had research grants from Brain Canada, Canada Foundation for Innovation (CFI), Canadian Institutes of Health Research (CIHR), and the Ontario Brain Institute in Canada. Other authors declare no competing financial interests.Clinical TrialNCT01655706Clinical Protocols https://osf.io/79gv8/?view_only=9e105962ce4c4ebf8cf35393471a7b69 Funding StatementCAN-BIND is an Integrated Discovery Program carried out in partnership with, and financial support from, the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario government. The opinions, results and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian Institutes of Health Research (CIHR), Lundbeck, and Servier. Funding and/or in-kind support is also provided by the investigators' universities and academic institutions. All study medications are independently purchased at wholesale market values. We acknowledge support to Gwen van der Wijk in the form of a Mamdani Family Foundation Graduate Scholarship and Alberta Graduate Excellence Scholarship (AGES: International). The funders had no role in the design, analysis, interpretation, or publication of this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from all participating centres. The ethics committees include: UBC Clinical Research Ethics Board (Vancouver); UCA Conjoint Health Research Ethics Board (Calgary); University Health Network Research Ethics Board (Toronto); CAM Research Ethics Board (Toronto); Hamilton Integrated Research Ethics Board (Hamilton); and QNS Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (Kingston). The participants provided written, informed consent for all study procedures.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this manuscript has been collected as part of the CAN-BIND initiative, an Integrated Discovery Program of the Ontario Brain Institute (OBI). OBI has released data from CAN-BIND's foundational study which aims to identify biomarkers that predict treatment response in people with depression. The dataset currently available on Brain-CODE includes baseline and longitudinal data from participant follow-up visits in weeks 2 to 8 of the study (Phase 1). All data have been standardized, cleaned and curated to maximize utility for analysis across different data modalities, and imaging data was converted to a BIDS-friendly naming convention. For access requirements, please visit OBI's Brain-CODE Neuroinformatics Platform (https://www.braincode.ca/) or email info{at}braininstitute.ca. https://www.braincode.ca/